0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Patient and Physician Convenience and the Choice of Intravitreal Anti–Vascular Endothelial Growth Factor Medications

John T. Thompson, MD1
[+] Author Affiliations
1Department of Ophthalmology, Greater Baltimore Medical Center, Baltimore, Maryland
JAMA Ophthalmol. 2016;134(1):49-50. doi:10.1001/jamaophthalmol.2015.4115.
Text Size: A A A
Published online

Extract

The article by Holfinger and colleagues1 in this issue of JAMA Ophthalmology provides an important analysis of how enforcement of patient-specific prescriptions (PSPs) alters the use of bevacizumab (Avastin). Bevacizumab for intravitreal use must be repackaged under sterile conditions in adherence to the US Pharmacopoeia 797 guidelines (http://www.usp.org). Retina specialists before 2012 were accustomed to ordering bevacizumab in syringes from compounding pharmacies. Multiple syringes of bevacizumab could be ordered without any requirement for identifying which patient received a particular dose or a particular lot. As a result of the tragic outbreak of meningitis from contaminated methylprednisolone for spinal injection prepared by New England Compounding Center, many states created or enforced existing regulations concerning the preparation of medications by compounding pharmacies. Patient-specific prescriptions were required in about one-third of the states by 2013. This requirement meant that retina specialists had to order bevacizumab for a particular patient 1 to 2 weeks before the patient came for an appointment (owing to compounding pharmacy processing and shipping times), or the patient had to return 1 to 2 weeks after his or her appointment to receive the bevacizumab. In the meantime, some patients with recurrent activity of their choroidal neovascularization or increased macular edema would experience visual loss while waiting for their dose of bevacizumab to arrive. The net effect of these requirements was less convenience for patients who had to return for their injection, many of whom are elderly and depend on others to drive them to their appointments. If retina specialists ordered bevacizumab in anticipation of their patient’s appointment, they would not infrequently have to discard unused syringes of bevacizumab when patients did not return for appointments or did not need the bevacizumab injection. Because the patient did not receive the medication, the patient could not be billed and the retina specialist lost the cost of the bevacizumab dose.

Topics

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

352 Views
0 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Jobs
brightcove.createExperiences();